Changchun BCHT Biotechnology

Changchun BCHT Biotechnology EBIT per Share

The EBIT per Share of Changchun BCHT Biotechnology (688276.SS) as of Nov 7, 2026 is -0.91 CNY. In the previous year, EBIT per Share was 0.62 CNY — a change of -246.11% (lower).

EBIT per Share

-0.91CNY

YoY

-246.11%

Last updated:

EBIT per Share of Changchun BCHT Biotechnology is 2025 -0.91 CNY. EBIT per Share of Changchun BCHT Biotechnology was 2024 0.62 CNY. It decreases by -246.11% lower compared to the previous year.

The Changchun BCHT Biotechnology EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2021
0.65 CNY
Jan 1, 2022
0.46 CNY
Jan 1, 2023
1.35 CNY
Jan 1, 2024
0.62 CNY
Jan 1, 2025
-0.91 CNY
Jan 1, 2026 (e)
-0.22 CNY
Jan 1, 2027 (e)
-0.03 CNY
Jan 1, 2028 (e)
0.09 CNY
The Changchun BCHT Biotechnology EBIT per Share history
YEAREBIT per ShareYoY
est0.09CNY-439.49%
est-0.03CNY-88.47%
est-0.22CNY-75.58%
-0.91CNY-246.11%
0.62CNY-53.96%
1.35CNY+191.79%
0.46CNY-28.33%
0.65CNY-50.18%
1.29CNY+72.18%
0.75CNY+101.08%
0.37CNY+30.97%
0.29CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Changchun BCHT Biotechnology Stock analysis

What does Changchun BCHT Biotechnology do? Changchun BCHT Biotechnology Co. generates revenue through the research and development, production, and sale of human vaccines. The company operates from its headquarters in Changchun, Jilin, and leverages a workforce of 1,252 full-time employees to support its core business activities. Its primary market focus is the domestic market, where it distributes its approved vaccine products to customers seeking prevention and control solutions for infectious diseases. The firm's product portfolio includes three approved vaccines: the varicella vaccine, the rabies vaccine, and the freeze-dried nasal spray flu vaccine. These established products form the basis of its current commercial operations. Additionally, the company is expanding its pipeline with other vaccines under development, alongside a fully human monoclonal antibody also in development, to further address the needs of the infectious disease prevention sector. Changchun BCHT Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Changchun BCHT Biotechnology stock

EBIT per Share of Changchun BCHT Biotechnology is -0.91 CNY in 2025.

EBIT per Share of Changchun BCHT Biotechnology changed from 0.62 CNY to -0.91 CNY, representing a -246.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Changchun BCHT Biotechnology since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Changchun BCHT Biotechnology

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Changchun BCHT Biotechnology